Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding

Autor: Pedro Miguel Lacal, Stefania D'Atri, Veronica Morea, Cristina Maria Failla, Elena Bonanno, Manuel Scimeca, Grazia Graziani, Federica Ruffini, Maria Grazia Atzori, Annalisa Susanna Dorio, Lucio Tentori

Publikováno v: Oncotarget
Oncotarget 7 (2016): 72868–72885. doi:10.18632/oncotarget.12108
info:cnr-pdr/source/autori:Graziani, Grazia; Ruffini, Federica; Tentori, Lucio; Scimeca, Manuel; Dorio, Annalisa S.; Atzori, Maria Grazia; Failla, Cristina M.; Morea, Veronica; Bonanno, Elena; D'Atri, Stefania; Lacal, Pedro M./titolo:Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding/doi:10.18632%2Foncotarget.12108/rivista:Oncotarget/anno:2016/pagina_da:72868/pagina_a:72885/intervallo_pagine:72868–72885/volume:7

Vascular endothelial growth factor receptor-1 (VEGFR-1) is a tyrosine kinase transmembrane receptor that has also a soluble isoform containing most of the extracellular ligand binding domain (sVEGFR-1). VEGF-A binds to both VEGFR-2 and VEGFR-1, where

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::210f302d2289624dc64e51cfac7bb5ca
https://doi.org/10.18632/oncotarget.12108

The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma

Autor: Anna Maria Caccuri, Emanuela Mazzon, Salvatore Cuzzocrea, Giorgio Federici, Patrizia Vernole, Grazia Graziani, Alessia Muzi, Annalisa Susanna Dorio, Andrea Sau, Lucio Tentori

Publikováno v: European Journal of Cancer. 47:1219-1230

First line treatment of metastatic melanoma includes the methylating agent dacarbazine or its analogue temozolomide (TMZ) with improved pharmacokinetics and tolerability. However, the prognosis of the metastatic disease is poor and several trials are

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8816e282c0cb5ddb2e14e4d742cffc20
https://doi.org/10.1016/j.ejca.2010.12.008

Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells

Autor: Annalisa Susanna Dorio, Alessia Muzi, Antonio Volpi, Alessandro Terrinoni, Girish M. Shah, Grazia Graziani, Patrizia Vernole

Publikováno v: Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 664:39-47

Mismatch repair (MMR) has been shown to control homologous recombination (HR) by aborting strand exchange between divergent sequences. We previously demonstrated that MMR-deficient tumour cells are more resistant to chromosomal damage induced by bleo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0980b4e6a32456a83c51b4f01d9f6a13
https://doi.org/10.1016/j.mrfmmm.2009.02.005

Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan

Autor: Annalisa Susanna Dorio, Federica Campolo, Lucio Tentori, Carlo Leonetti, Manuela Porru, Susanna Dolci, Alessia Muzi, Françoise Praz, Pedro Miguel Lacal, Patrizia Vernole, Grazia Graziani

Poly(ADP-ribose) polymerase inhibitors (PARPi) are currently evaluated in clinical trials in combination with topoisomerase I (Top1) inhibitors against a variety of cancers, including colon carcinoma. Since the mismatch repair component MLH1 is defec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c03cfeef0c9f037ea1e4dcc4c492fa6
http://hdl.handle.net/11573/1411689

Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells

Autor: Annalisa Susanna Dorio, Grazia Graziani, Alessia Muzi, Domenico Fulgione, Piera Quesada, Giovanna D’Onofrio, Maria Malanga, Valeria Maselli, Filomena Tramontano

Publikováno v: Biochemical pharmacology. 81(2)

A molecular approach to enhance the antitumour activity of topoisomerase 1 (TOP1) inhibitors relies on the use of chemical inhibitors of poly(ADP-ribose)polymerases (PARP). Poly(ADP-ribosyl)ation is involved in the regulation of many cellular process

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec836a15ba527fb3492a7866274a8af5
https://pubmed.ncbi.nlm.nih.gov/20875401